Investors
Oct 12, 2026
Taipei, Taiwan, 12 October 2026 — Lotus Pharmaceutical Co., Ltd. (Taiwan Stock Exchange: 1795), a global pharmaceutical leader based in Taiwan, today announced its unaudited consolidated revenue for September 2026 of NT$2,766 million, repr...
Business
Oct 7, 2026
Taipei, Taiwan, and Seoul, South Korea, 07 October 2026 — Lotus Pharmaceutical Co., Ltd. (Taiwan Stock Exchange: 1795), a global pharmaceutical company headquartered in Taiwan, today announced the completion of the acquisition of the South Kore...
Business
Sep 24, 2026
Taipei, Taiwan, 24 September 2026 — Lotus Pharmaceutical Co., Ltd. (Taiwan Stock Exchange: 1795), a leading global pharmaceutical company, today announced that the U.S. Food and Drug Administration (FDA) has accepted for filing an Abbreviated N...
Investors
Sep 10, 2026
Taipei, Taiwan, 10 September 2026 — Lotus Pharmaceutical Co., Ltd. (Taiwan Stock Exchange: 1795), a global pharmaceutical leader based in Taiwan, today announced its unaudited consolidated revenue for August 2026 of NT$2,107 million, repre...
ESG
Aug 27, 2026
Taipei, Taiwan, 27 August 2026 — Lotus Pharmaceutical Co., Ltd. (Taiwan Stock Exchange: 1795), a leading global pharmaceutical company, today announced that it has received the Gold Award in the Social Inclusion category at the 2026 Taiwan Sust...
Business
Aug 26, 2026
Taipei, Taiwan and Morristown, N.J., 26 August 2026 — Lotus Pharmaceutical Co., Ltd. (Taiwan Stock Exchange: 1795), a leading global pharmaceutical company, today announced that Norwich Pharmaceuticals, Inc. (“Norwich”), a wholly ow...
